- Home
- SNDX vs CIM Comparison
SNDX vs CIM Comparison
Compare SNDX & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- CIM
- Stock Information
- Founded
- SNDX 2005
- CIM 2007
- Country
- SNDX United States
- CIM United States
- Employees
- SNDX N/A
- CIM N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- CIM Real Estate Investment Trusts
- Sector
- SNDX Health Care
- CIM Real Estate
- Exchange
- SNDX Nasdaq
- CIM Nasdaq
- Market Cap
- SNDX 974.9M
- CIM 865.9M
- IPO Year
- SNDX 2016
- CIM 2007
- Fundamental
- Price
- SNDX $11.54
- CIM $11.39
- Analyst Decision
- SNDX Strong Buy
- CIM Hold
- Analyst Count
- SNDX 10
- CIM 2
- Target Price
- SNDX $36.20
- CIM $16.00
- AVG Volume (30 Days)
- SNDX 1.9M
- CIM 867.7K
- Earning Date
- SNDX 05-07-2025
- CIM 05-08-2025
- Dividend Yield
- SNDX N/A
- CIM 13.01%
- EPS Growth
- SNDX N/A
- CIM 61.77
- EPS
- SNDX N/A
- CIM 1.10
- Revenue
- SNDX $23,680,000.00
- CIM $277,886,000.00
- Revenue This Year
- SNDX $286.51
- CIM $9.17
- Revenue Next Year
- SNDX $120.86
- CIM $1.73
- P/E Ratio
- SNDX N/A
- CIM $10.35
- Revenue Growth
- SNDX N/A
- CIM 22.95
- 52 Week Low
- SNDX $9.66
- CIM $9.85
- 52 Week High
- SNDX $25.07
- CIM $16.89
- Technical
- Relative Strength Index (RSI)
- SNDX 44.37
- CIM 39.57
- Support Level
- SNDX $9.66
- CIM $10.94
- Resistance Level
- SNDX $11.61
- CIM $11.30
- Average True Range (ATR)
- SNDX 1.01
- CIM 0.62
- MACD
- SNDX 0.02
- CIM -0.03
- Stochastic Oscillator
- SNDX 56.12
- CIM 49.68
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.